This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Abbott (ABT) Gains CE Mark for Quantitative Serology Testing
by Zacks Equity Research
The test is set to be used on Abbott's (ABT) ARCHITECT and Alinity i platforms.
Abbott (ABT) Stock Moves -0.23%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $106.79 in the latest trading session, marking a -0.23% move from the prior day.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Stock
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and shipments.
Abbott (ABT) Launches Immunity Boosting Hydration Solution
by Zacks Equity Research
Abbott's (ABT) latest hydration solution with specifically chosen nutrients along with optimal balance of electrolytes and glucose is expected to boost immunity.
3 Beaten-Down MedTech Stocks Set to Stage a Comeback in 2021
by Sriparna Ghosal
Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.
Abbott (ABT) Stock Moves -0.45%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $106.32, moving -0.45% from the previous trading session.
4 Top-Ranked MedTech Stocks to Bet on Heading Into 2021
by Trina Mukherjee
Grab these four top stocks that have shown tremendous promise despite market volatility due to the pandemic and have the potential to continue their bull run in 2021.
Abbott's (ABT) Libre 2 Cleared in Canada, Boosts CGM Prospects
by Zacks Equity Research
Abbott's (ABT) next-generation FreeStyle Libre 2 system aims to provide a better quality of life to diabetics in Canada at the same affordable price of the current FreeStyle Libre system.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $107.53, marking a -0.57% move from the previous day.
4 MedTech Stocks Gaining Ground on COVID-19 Test Kit Success
by Debanjana Dey
Here are a few coronavirus-testing MedTech stocks that investors can scoop up to reap profits amid the pandemic-battered stock market situation.
Pediatric Medical Space Thrives Amid COVID-19: 3 Stocks in Focus
by Zacks Equity Research
Among several domains within the MedTech space, several pediatric medical device stocks have been gaining traction amid the coronavirus pandemic
The Zacks Analyst Blog Highlights: NVIDIA, Pfizer, Abbott, UPS and ICICI
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVIDIA, Pfizer, Abbott, UPS and ICICI
Top Stock Reports for NVIDIA, Pfizer & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Pfizer (PFE) and Abbott Laboratories (ABT).
Why Is Abbott (ABT) Up 1.4% Since Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Launches Radiofrequency Ablation Device in U.S.
by Zacks Equity Research
Abbott (ABT) aims to expand its Neuromodulation portfolio with the latest launch of its radiofrequency ablation device.
Zacks Industry Outlook Highlights: Abbott Laboratories, Baxter International, ResMed and Intuitive Surgical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Abbott Laboratories, Baxter International, ResMed and Intuitive Surgical
3 Stocks to Capitalize on Promising Medical Products Industry
by Trina Mukherjee
Despite the challenges triggered by the COVID-19 pandemic, higher demand for IVD products, digital influence and AI & Robotics are likely to lend support to the Zacks Medical - Products industry. ABT, BAX and RMD are well positioned to gain from the prospects.
3 Medical Product Stocks Poised to Beat This Earnings Season
by Trina Mukherjee
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, on the back of several factors.
Top Stock Reports for Microsoft, Tesla & AT&T
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Tesla (TSLA) and AT&T (T).
Surging Earnings Estimates Signal Upside for Abbott (ABT) Stock
by Zacks Equity Research
Abbott (ABT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
BD's (BDX) COVID-19 Real-Time PCR Detection Kit Gets CE Mark
by Zacks Equity Research
BD's (BDX) Real Time PCR Detection Kit enables BD MAX System users to run a single module that tests concurrently for COVID-19, flu and RSV.
OPKO Health's (OPK) BioReference Laboratories Unveils New Test
by Zacks Equity Research
OPKO Health's (OPK) BioReference Laboratories' new multiplex test can differentiate between COVID-19 and Influenza infections with a single sample.
Abbott (ABT) Q3 Earnings Top, Diagnostic Test Sales Solid
by Zacks Equity Research
In Q3, Abbott (ABT) registers solid worldwide adoption of FreeStyle Libre System.
Verizon (VZ), Abbott (ABT), Thermo Fisher (TMO) Report Q3; Tesla (TSLA) After the Bell
by Mark Vickery
Thermo Fisher (TMO) posted a big beat this morning, while Verizon (VZ) and Abbott (ABT) topped expectations more mildly.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge